Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 13/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509221 | 0.83 | STK17B (0.42) | STK17BSTK17AAAK1BTK | |
| SCHEMBL31380404 | 0.80 | STK17B (0.53) | STK17BSTK17ACKS1BSKP1SKP2 | |
| SCHEMBL6509042 | 0.78 | CDK1 (0.70) | CDK1KDR | |
| SCHEMBL6508416 | 0.77 | STK17B (0.49) | STK17BSTK17AAAK1TRPV1CKS1B | |
| SCHEMBL6513724 | 0.76 | CDK1 (0.45) | BTKCDK1KDR | |
| SCHEMBL31247637 | 0.75 | GAA (0.43) | STK17BSTK17AAAK1 | |
| SCHEMBL34464819 | 0.73 | STK17B (0.41) | STK17BSTK17AAAK1BTKCDK1 | |
| SCHEMBL16586284 | 0.72 | MAPKAPK2 (0.47) | STK17BSTK17A | |
| SCHEMBL34471867 | 0.72 | HTT (0.42) | AAK1 | |
| SCHEMBL5385077 | 0.71 | MAP2K4 (0.47) | BTKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222175-B1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | CELLTECH R&D LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2005-08-04 | — | — | US | disclosed |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | DAVIS JEREMY MARTIN (GB) | 2003-11-13 | — | — | US | disclosed |
| US-6600037-B1 | The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis. | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
| EP-1222175-A1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | Celltech R&D Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001029009-A1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | CELLTECH R&D LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FLT4, FGFR1 | STK17B 3074/4885STK17A 3227/4885AAK1 2762/4885 |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | STK17B 3540/4885STK17A 3642/4885AAK1 1970/4885 |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | STK17B 3535/4885STK17A 3647/4885AAK1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.